Aurobindo Pharma Ltd. reported fourth-quarter net profit slid less than 1% to ₹528.76 crore from ₹532.22 crore a year earlier.Revenue from operations Aurobindo Pharma Ltd. reported fourth-quarter net profit slid less than 1% to ₹528.76 crore from ₹532.22 crore a year earlier. Revenue from operations grew 11.2% to ₹4,049.1 crore. A 43.3% decline in anti-retroviral product portfolio sales to ₹148.6 crore impacted performance. The company, however, registered sales growth in the formulations business in the U.S., Europe and Growth Markets. Total formulations, including ARV, grew 12.8% to ₹3,248.6 crore during the quarter. The company reported a 4.8% increase in the API sales to ₹799.6 crore. For the full fiscal, net profit grew by over 5% to ₹2,422.92 crore (₹2,301.2 crore), while the total revenue from operations increased by 9.3% at ₹16,499.8 crore (₹15,089.9 crore). Managing director N. Govindarajan said the company has reported a healthy growth in revenues and profitability in ...
Comments
Post a Comment